Substrate reduction therapy in a <i>Drosophila melanogaster</i> model of Sanfilippo syndrome
Sher Li Tan(South Australian Health and Medical Research Institute), Adeline A. Lau(Flinders University), Qi He(The University of Queensland), Kim M. Hemsley(South Australian Health and Medical Research Institute), Paul J. Trim(South Australian Health and Medical Research Institute), Norbert Wimmer(The University of Queensland), Vito Ferro(The University of Queensland), Marten F. Snel(South Australian Health and Medical Research Institute), Nooramirah Farhana Mustaffar(The University of Queensland), Barbara King(Flinders University), Louise V. O’Keefe(South Australian Health and Medical Research Institute), Laura J. Hewson(The University of Adelaide)
Cited by 1
Related Papers
Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA
|Experimental Neurology|2018|19
The role of microRNA miR223 in immune adaptation for pregnancy and fetal-placental development
|Placenta|2015|3
<scp><i>Drosophila melanogaster</i></scp>models of<scp>MPS IIIC</scp>(<scp><i>Hgsnat</i></scp>‐deficiency) highlight the role of glia in disease presentation
|Journal of Inherited Metabolic Disease|2024|3
Substrate reduction using a glucosamine analogue in Drosophila melanogaster and mouse models of Sanfilippo syndrome
|Molecular Genetics and Metabolism|2025|0